Resveratrol given intraperitoneally does not inhibit the growth of high-risk t(4;11) acute lymphoblastic leukemia cells in a NOD/SCID mouse model

Susan J. Zunino, David H. Storms, John W. Newman, Theresa L. Pedersen, Carl L Keen, Jonathan M Ducore

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The efficacy of resveratrol as a preventive agent against the growth of t(4;11) acute lymphoblastic leukemia (ALL) was evaluated in NOD.CB17-Prkdcscid/J mice engrafted with the human t(4;11) ALL SEM cell line. SEM cells were injected into the tail vein and engraftment was monitored by flow cytometry. Once engraftment was observed, mice were injected intraperitoneally with resveratrol (10 mg/kg body weight) dissolved in dimethylsulfoxide (DMSO) or DMSO alone (control) every other day, or vincristine (0.5 mg/kg body weight) 3 times per week for 4 weeks (n=16 per group). Comparisons of the percent of human leukemia cells in blood and survival curves showed resveratrol did not inhibit progression of the disease. Liquid chromatography-tandem mass spectrometry analyses of mouse sera showed resveratrol was rapidly metabolized to glucuronidated and sulfated forms 1 h post-injection, with low to no resveratrol or metabolites observed in sera by 24-48 h. These data indicate that in contrast to findings in in vitro models, parenterally administered resveratrol does not have potential as a preventive agent against high risk t(4;11) ALL.

Original languageEnglish (US)
Pages (from-to)1277-1284
Number of pages8
JournalInternational Journal of Oncology
Volume40
Issue number4
DOIs
StatePublished - Apr 2012

Fingerprint

Inbred NOD Mouse
SCID Mice
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Growth
Dimethyl Sulfoxide
Body Weight
Vincristine
Tandem Mass Spectrometry
Serum
Liquid Chromatography
Disease Progression
resveratrol
Tail
Veins
Blood Cells
Flow Cytometry
Leukemia
Cell Line
Injections
Survival

Keywords

  • Metabolites
  • NOD/SCID mice
  • Resveratrol
  • t(4;11) acute lymphoblastic leukemia
  • Vincristine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Resveratrol given intraperitoneally does not inhibit the growth of high-risk t(4;11) acute lymphoblastic leukemia cells in a NOD/SCID mouse model. / Zunino, Susan J.; Storms, David H.; Newman, John W.; Pedersen, Theresa L.; Keen, Carl L; Ducore, Jonathan M.

In: International Journal of Oncology, Vol. 40, No. 4, 04.2012, p. 1277-1284.

Research output: Contribution to journalArticle

Zunino, Susan J. ; Storms, David H. ; Newman, John W. ; Pedersen, Theresa L. ; Keen, Carl L ; Ducore, Jonathan M. / Resveratrol given intraperitoneally does not inhibit the growth of high-risk t(4;11) acute lymphoblastic leukemia cells in a NOD/SCID mouse model. In: International Journal of Oncology. 2012 ; Vol. 40, No. 4. pp. 1277-1284.
@article{d4e4c6c4b853487ca2eb82ea0e1ffc51,
title = "Resveratrol given intraperitoneally does not inhibit the growth of high-risk t(4;11) acute lymphoblastic leukemia cells in a NOD/SCID mouse model",
abstract = "The efficacy of resveratrol as a preventive agent against the growth of t(4;11) acute lymphoblastic leukemia (ALL) was evaluated in NOD.CB17-Prkdcscid/J mice engrafted with the human t(4;11) ALL SEM cell line. SEM cells were injected into the tail vein and engraftment was monitored by flow cytometry. Once engraftment was observed, mice were injected intraperitoneally with resveratrol (10 mg/kg body weight) dissolved in dimethylsulfoxide (DMSO) or DMSO alone (control) every other day, or vincristine (0.5 mg/kg body weight) 3 times per week for 4 weeks (n=16 per group). Comparisons of the percent of human leukemia cells in blood and survival curves showed resveratrol did not inhibit progression of the disease. Liquid chromatography-tandem mass spectrometry analyses of mouse sera showed resveratrol was rapidly metabolized to glucuronidated and sulfated forms 1 h post-injection, with low to no resveratrol or metabolites observed in sera by 24-48 h. These data indicate that in contrast to findings in in vitro models, parenterally administered resveratrol does not have potential as a preventive agent against high risk t(4;11) ALL.",
keywords = "Metabolites, NOD/SCID mice, Resveratrol, t(4;11) acute lymphoblastic leukemia, Vincristine",
author = "Zunino, {Susan J.} and Storms, {David H.} and Newman, {John W.} and Pedersen, {Theresa L.} and Keen, {Carl L} and Ducore, {Jonathan M}",
year = "2012",
month = "4",
doi = "10.3892/ijo.2011.1316",
language = "English (US)",
volume = "40",
pages = "1277--1284",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Resveratrol given intraperitoneally does not inhibit the growth of high-risk t(4;11) acute lymphoblastic leukemia cells in a NOD/SCID mouse model

AU - Zunino, Susan J.

AU - Storms, David H.

AU - Newman, John W.

AU - Pedersen, Theresa L.

AU - Keen, Carl L

AU - Ducore, Jonathan M

PY - 2012/4

Y1 - 2012/4

N2 - The efficacy of resveratrol as a preventive agent against the growth of t(4;11) acute lymphoblastic leukemia (ALL) was evaluated in NOD.CB17-Prkdcscid/J mice engrafted with the human t(4;11) ALL SEM cell line. SEM cells were injected into the tail vein and engraftment was monitored by flow cytometry. Once engraftment was observed, mice were injected intraperitoneally with resveratrol (10 mg/kg body weight) dissolved in dimethylsulfoxide (DMSO) or DMSO alone (control) every other day, or vincristine (0.5 mg/kg body weight) 3 times per week for 4 weeks (n=16 per group). Comparisons of the percent of human leukemia cells in blood and survival curves showed resveratrol did not inhibit progression of the disease. Liquid chromatography-tandem mass spectrometry analyses of mouse sera showed resveratrol was rapidly metabolized to glucuronidated and sulfated forms 1 h post-injection, with low to no resveratrol or metabolites observed in sera by 24-48 h. These data indicate that in contrast to findings in in vitro models, parenterally administered resveratrol does not have potential as a preventive agent against high risk t(4;11) ALL.

AB - The efficacy of resveratrol as a preventive agent against the growth of t(4;11) acute lymphoblastic leukemia (ALL) was evaluated in NOD.CB17-Prkdcscid/J mice engrafted with the human t(4;11) ALL SEM cell line. SEM cells were injected into the tail vein and engraftment was monitored by flow cytometry. Once engraftment was observed, mice were injected intraperitoneally with resveratrol (10 mg/kg body weight) dissolved in dimethylsulfoxide (DMSO) or DMSO alone (control) every other day, or vincristine (0.5 mg/kg body weight) 3 times per week for 4 weeks (n=16 per group). Comparisons of the percent of human leukemia cells in blood and survival curves showed resveratrol did not inhibit progression of the disease. Liquid chromatography-tandem mass spectrometry analyses of mouse sera showed resveratrol was rapidly metabolized to glucuronidated and sulfated forms 1 h post-injection, with low to no resveratrol or metabolites observed in sera by 24-48 h. These data indicate that in contrast to findings in in vitro models, parenterally administered resveratrol does not have potential as a preventive agent against high risk t(4;11) ALL.

KW - Metabolites

KW - NOD/SCID mice

KW - Resveratrol

KW - t(4;11) acute lymphoblastic leukemia

KW - Vincristine

UR - http://www.scopus.com/inward/record.url?scp=84858692173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858692173&partnerID=8YFLogxK

U2 - 10.3892/ijo.2011.1316

DO - 10.3892/ijo.2011.1316

M3 - Article

C2 - 22200740

AN - SCOPUS:84858692173

VL - 40

SP - 1277

EP - 1284

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 4

ER -